Pharma Update

Roche 2023: Key late-stage newsflow* Regulatory Compound Hemlibra Polivy + R-CHP Vabysmo Tecentriq Columvi (glofitamab) Xofluza Tecentriq + Avastin Tecentriq + chemo Tecentriq Tecentriq + chemo Tiragolumab + Tecentriq Tiragolumab + Tecentriq + chemo Venclexta + dexamethasone Venclexta + azacitidine Alecensa Indication Moderate hemophilia A 1L DLBCL RVO Subcutaneous administration 3L+ DLBCL Influenza (paediatric 1+ yrs.) Adjuvant HCC Neoadjuvant/adjuvant TNBC Adjuvant SCCHN Adjuvant TNBC 1L PDL 1+ NSCLC 1L esophageal cancer t(11;14) R/R MM 1L high risk MDS Milestone EU approval US approval US approval/EU filing US approval/EU filing US/EU approval EU approval Ph III IMbrave050 Ph III IMvoke010 Ph III IMpassion030 EU filing US 2024/ EU filing Ph III GeparDouze/NSABP B-59 2024 Х Q4 2023/Q1 2024 Ph III SKYSCRAPER-08 (China only) Ph III CANOVA Ph III SKYSCRAPER-01 2024 Phase III/ pivotal readouts Phesgo OBI (on body injector) Crovalimab Columvi + GemOx Lunsumio + Polivy Elevidys (Delandistrogene moxeparvovec) Ocrevus 6m SC TNKase Susvimo Susvimo Xolair Adjuvant ALK+ NSCLC HER2+ BC PNH 2L+ DLBCL 2L+ DLBCL DMD RMS/PPMS Stroke patients 4.5-24h DME DR Food allergy Ph III VERONA Ph III ALINA Ph I (pivotal) Ph III COMMODORE 1/2 Ph III STARGLO Ph III SUNMO Ph III EMBARK Ph III OCARINA II Ph III TIMELESS Ph III PAGODA Ph III PAVILION Ph III OUTMATCH ༨.༨༥༨ སྤ་ཚོད་ ༨ Additional 2023 newsflow: * Outcome studies are event-driven: timelines may change Fenebrutinib: Positive Ph II (FENopta) results in RMS • Elevidys US approval in DMD for 4 and 5 years old (Sarepta) • Tiragolumab + Tecentriq + Avastin: Positive Ph I/II (MORPHEUS) results in 1L HCC • Inavolisib + palbociclib + fulvestrant Ph III (INAVO120) data expected Q4 2023 62

View entire presentation